Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

BioScience Health Innovations (BHIC) Receivables - Other (2024 - 2025)

BioScience Health Innovations has reported Receivables - Other over the past 2 years, most recently at $137718.0 for Q4 2025.

  • Quarterly Receivables - Other rose 531.79% to $137718.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $137718.0 through Dec 2025, up 531.79% year-over-year, with the annual reading at $137718.0 for FY2025, 531.79% up from the prior year.
  • Receivables - Other was $137718.0 for Q4 2025 at BioScience Health Innovations, up from $21798.0 in the prior quarter.
  • Over five years, Receivables - Other peaked at $137718.0 in Q4 2025 and troughed at $21798.0 in Q4 2024.